浩欧博股价下跌1.61% 上半年净利润同比下降39.10%

Group 1 - The stock price of Haobor is reported at 112.90 yuan, down 1.85 yuan or 1.61% from the previous trading day, with a trading volume of 10,347 hands and a transaction amount of 118 million yuan [1] - Haobor's main business involves the research, production, and sales of in vitro diagnostic reagents, primarily used in the diagnosis of allergies and autoimmune diseases. The company holds 62 patents and 230 product registration certificates, utilizing core technologies such as enzyme-linked immunosorbent assay and nano-magnetic chemiluminescence technology [1] - According to the 2025 semi-annual report, Haobor achieved a revenue of 190 million yuan in the first half of the year, a year-on-year decrease of 6.48%, with a net profit attributable to shareholders of 12.17 million yuan, down 39.10% year-on-year. The decline in performance is mainly attributed to a decrease in product sales scale and an increase in costs [1] - In the second quarter, the revenue was 112 million yuan, a year-on-year decrease of 4.4%, and the net profit was 10.53 million yuan, down 34.9% year-on-year [1] Group 2 - In terms of capital flow, Haobor experienced a net outflow of 11.20 million yuan from main funds on the day, with a cumulative net outflow of 3.78 million yuan over the past five days [2]